Compare Novartis AG (NVS) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vital Farms Inc — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while Vital Farms Inc trades at $9.45 (market cap $396.69M). The key difference: Novartis AG is far larger — about 677× Vital Farms Inc's market cap, and Novartis AG pays a 3.31% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Vital Farms Inc for 14 Days on average.
| NVS | VITL | |
|---|---|---|
Market Cap | $268.57B | $396.69M |
Volume | 1,532,573 | 1,219,207 |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $43.68 |
52-Week Low | $121.80 | $8.28 |
Typical Hold Time | 82 Days | 14 Days |
Enterprise Value | $309.89B | $483.70M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Vital Farms (VITL) trades at $9.24, down 1.7% on the day, amid a bearish technical signal and challenging fundamentals. Recent earnings show volatility with a Q2 2026 loss of $0.47 per share, though it slightly beat expectations, while revenue declined 10% year-over-year in that quarter. The company faces pressure from egg pricing and oversupply, as noted in recent news, but maintains a 'Buy' consensus from analysts with a $13.11 price target.
The outlook is mixed: strong analyst support and potential strategic options like a sale offer upside, but weak profitability margins and cash flow concerns pose significant risks. Investors should weigh the company's market position against ongoing industry headwinds and execution challenges in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
